[CNAT] Conatus Pharmaceuticals Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 4.43 Change: 0.66 (17.51%)
Ext. hours: 4.43 Change: 0 (0%)

chart CNAT

Refresh chart

Description: Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its products include Emricasan, an orally active pan-caspase protease inhibitor for the treatment of acute-on-chronic liver failure; chronic liver failure; post liver transplant clearance of hepatitis C virus infection with sustained viral response; non-alcoholic steatohepatitis; and nonalcoholic fatty liver disease. The company was founded in 2005 and is headquartered in San Diego, California.

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-71.33% ROE-82.04% ROI
Current Ratio10.09 Quick Ratio Long Term Debt/Equity0.04 Debt Ratio0.11
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-30 K Cash From Investing Activities4.37 M Cash From Operating Activities-5.95 M Gross Profit
Net Profit-5.98 M Operating Profit-5.96 M Total Assets32.32 M Total Current Assets31.54 M
Total Current Liabilities3.13 M Total Debt1000 K Total Liabilities4.22 M Total Revenue
Technical Data
High 52 week7.5 Low 52 week3.3 Last close3.99 Last change-1.48%
RSI25.76 Average true range0.23 Beta1.35 Volume6.13 M
Simple moving average 20 days-8.38% Simple moving average 50 days-10.25% Simple moving average 200 days-14.59%
Performance Data
Performance Week-4.09% Performance Month-12.69% Performance Quart8.42% Performance Half-28.24%
Performance Year-25.97% Performance Year-to-date-13.64% Volatility daily2.66% Volatility weekly5.95%
Volatility monthly12.2% Volatility yearly42.25% Relative Volume56874.5% Average Volume524.58 K
New High New Low

News

2018-12-28 17:40:10 | Conatus CNAT Focuses on Developing NASH Candidate Emricasan

2018-12-13 09:26:02 | The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis

2018-12-12 10:03:03 | Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate

2018-12-07 08:04:52 | The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut

2018-12-06 14:51:07 | Conatus' Emricasan Misses Primary Endpoint in Mid-Stage Study

2018-12-06 14:13:00 | Shares of Conatus Pharmaceuticals plummet over 50% after Phase 2 trial fails to meet primary endpoint

2018-12-06 07:00:00 | Today's Research Reports on Trending Tickers: Conatus Pharmaceuticals and Exelixis

2018-12-05 07:30:00 | Conatus Announces Results from ENCORE-PH Phase 2b Clinical Trial in NASH Cirrhosis

2018-11-16 10:42:47 | When Will Conatus Pharmaceuticals Inc NASDAQ:CNAT Become Profitable?

2018-11-16 07:50:00 | Investor Expectations to Drive Momentum within 2U, Broadwind Energy, Nuverra Environmental Solutions, Ability, ContraFect, and Conatus Pharmaceuticals — Discovering Underlying Factors of Influence

2018-11-14 08:46:01 | Do Options Traders Know Something About Conatus CNAT Stock We Don't?

2018-11-08 07:30:00 | Conatus Pharmaceuticals Announces Presentations and Posters at AASLD Annual Meeting

2018-11-02 12:30:04 | Conatus' CNAT Q3 Loss In Line, Revenues Lag Estimates

2018-11-02 12:13:05 | Edited Transcript of CNAT earnings conference call or presentation 1-Nov-18 8:30pm GMT

2018-11-02 07:30:11 | Conatus Pharmaceuticals CNAT Reports Q3 Loss, Misses Revenue Estimates

2018-11-02 05:03:24 | Conatus: 3Q Earnings Snapshot

2018-11-01 16:05:00 | Conatus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Program Updates

2018-10-25 07:30:00 | Conatus Pharmaceuticals to Report Third Quarter 2018 Financial Results

2018-10-22 08:00:00 | Today’s Research Reports on Stocks to Watch: Planet Green and The9 Limited

2018-10-11 08:51:12 | Options Traders Expect Huge Moves in Conatus Pharmaceuticals CNAT Stock

2018-10-02 16:05:00 | Conatus Pharmaceuticals Announces Three Accepted Abstracts for AASLD Annual Meeting

2018-09-25 08:00:00 | Conatus Pharmaceuticals, Upcoming Presentations, Analysts Review and Target

2018-09-20 07:30:00 | Conatus Pharmaceuticals to Host Analyst and Investor Symposium on Portal Hypertension

2018-09-19 08:00:00 | Today's Research Reports on Trending Tickers: Conatus Pharmaceuticals and INSYS Therapeutics

2018-09-19 07:30:00 | Conatus Pharmaceuticals to Participate in Upcoming Investor Conferences

2018-09-18 10:50:25 | Who Owns Most Of Conatus Pharmaceuticals Inc NASDAQ:CNAT?

2018-08-31 09:58:01 | Options Traders Expect Huge Moves in Conatus Pharmaceuticals CNAT Stock

2018-08-31 09:49:01 | Conatus CNAT Up 36.2% Since Last Earnings Report: Can It Continue?

2018-08-29 07:30:00 | Conatus Pharmaceuticals to Present at BioCentury NewsMakers Conference

2018-08-23 08:00:00 | Today's Research Reports on Trending Tickers: Conatus Pharmaceuticals and Sarepta Therapeutics

2018-08-02 11:47:03 | Conatus' CNAT Q2 Loss Narrows, Revenues Lag Marginally

2018-08-01 23:14:26 | Edited Transcript of CNAT earnings conference call or presentation 1-Aug-18 8:30pm GMT

2018-08-01 20:20:12 | Conatus Pharmaceuticals CNAT Reports Q2 Loss, Misses Revenue Estimates

2018-08-01 19:15:48 | Conatus: 2Q Earnings Snapshot

2018-08-01 16:05:00 | Conatus Pharmaceuticals Reports Second Quarter 2018 Financial Results and Program Updates

2018-07-30 12:15:04 | What's in the Cards for Conatus CNAT This Earnings Season?

2018-07-25 16:05:00 | Conatus Pharmaceuticals to Report Second Quarter 2018 Financial Results

2018-07-02 07:30:00 | Conatus Pharmaceuticals’ Pan-caspase Inhibitor Emricasan Improves Survival and Portal Hypertension in a Mouse Model of Cirrhosis

2018-06-14 09:23:01 | NASH Space in Focus as Galmed GLMD Posts Positive Data

2018-06-01 10:20:02 | Why Is Conatus Pharmaceuticals CNAT Up 4.1% Since Its Last Earnings Report?

2018-05-03 11:58:03 | Conatus' CNAT Q1 Loss In Line, Revenues Beat Estimates

2018-05-02 18:22:17 | Conatus: 1Q Earnings Snapshot

2018-05-02 16:05:00 | Conatus Pharmaceuticals Reports First Quarter 2018 Financial Results and Program Updates

2018-04-30 15:45:33 | Analysts’ Ratings for Amicus and Its Peers in April

2018-04-30 07:30:00 | Conatus Announces Completion of Enrollment in ENCORE-PH Phase 2b Clinical Trial of Emricasan in Patients with NASH Cirrhosis and Severe Portal Hypertension

2018-04-27 11:50:03 | What's in the Cards for Conatus CNAT This Earnings Season?

2018-04-25 16:05:00 | Conatus Pharmaceuticals to Report First Quarter 2018 Financial Results

2018-04-18 07:30:00 | Conatus Pharmaceuticals’ IDN-7314 Pan-caspase Inhibitor Reduces Hepatic Tissue Factor-Driven Coagulation In Vitro and In Vivo

2018-04-13 15:37:48 | How Analysts Rate Regenxbio and Peers in April 2018

2018-04-11 10:20:02 | Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis